GANCICLOVIR (gan-ci'clo-vir) Cytovene Classifications: antiinfective; antiviral agent Prototype: Acyclovir Pregnancy Category: C
|
250 mg, 500 mg capsules; 500 mg powder for injection
Ganciclovir is an antiviral drug active against cytomegalovirus (CMV). It prevents the replication CMV DNA.
Sensitive human viruses include CMV, herpes simplex virus-1 and -2 (HSV-1, HSV-2), Epstein-Barr virus, and varicella-zoster
virus.
CMV retinitis, prophylaxis and treatment of systemic CMV infections in immunocompromised patients including HIV-positive and
transplant patients.
Hypersensitivity to ganciclovir or acyclovir, lactation.
Renal impairment, older adults, pregnancy (category C). Safety and efficacy in children are not established.
Induction Therapy Adult/Child: IV >3 mo, 5 mg/kg over 1 h q12h for 1421 d (doses may range from 2.55.0 mg/kg over 1 h q812h for 1035 d)
Maintenance Therapy Adult: IV 5 mg/kg over 1 h qd or 6 mg/kg over 1 h qd 5 d/wk PO 1000 mg t.i.d. or 500 mg 6 times/d q3h while awake
Prevention of CMV Disease in Transplant Recipients Adult/Child: IV 5 mg/kg q12h 714 d, then 5 mg/kg q.d. or 6 mg/kg/d 5 d/wk
CMV Infection after Bone Marrow Transplant Child: IV 7.519.5 mg/kg/d divided q8h
Renal Impairment See prescribing information for dosing in patients with renal impairment
|
- Note: Do not administer if neutrophil count falls below 500/mm3 or platelet count falls below 25,000/mm3.
- Avoid direct contact of powder in capsules or solution with skin and mucous membranes. Wash thoroughly with soap and water
if contact occurs.
Oral
Intravenous
- IV administration to infants and children: Verify correct IV concentration and rate of infusion with physician.
PREPARE: Intermittent: • Reconstitute the 500-mg vial using only 10 mL of sterile water (supplied) for injection immediately before use to yield 50
mg/mL.• Shake well to dissolve.• Withdraw the ordered amount and add to 100 mL of NS, D5W, or RL (volume less than 100 mL may be used, but the final concentration
should be <10 mg/mL).
ADMINISTER: Intermittent: Give at a constant rate over 1 h. Avoid rapid infusion or bolus injection.
INCOMPATIBILITIES Solution/additive: Amino acid solutions (TPN), bacteriostatic water for injection, fludarabine, foscarnet, ondansetron. Y-site: Total parenteral nutrition.
|
- Store reconstituted solutions refrigerated at 4° C; use within 12 h.
- Store infusion solution refrigerated up to 24 h of preparation.
CNS: Fever, headache, disorientation, mental status changes, ataxia, coma, confusion, dizziness, paresthesia, nervousness, somnolence, tremor. CV: Edema, phlebitis. GI: Nausea, diarrhea, anorexia, elevated liver enzymes. Hematologic: Bone marrow suppression , thrombocytopenia, granulocytopenia, eosinophilia, leukopenia, hyperbilirubinemia. Metabolic: Hyperthermia, hypoglycemia. Urogenital: Infertility. Skin: Rash.
Drug: antineoplastic agents, amphotericin B, didanosine, trimethoprim-sulfa-methoxazole (TMP-SMZ), dapsone, pentamidine, probenecid, zidovudine may increase bone marrow suppression and other toxic effects of ganciclovir; may increase risk of nephrotoxicity from cyclosporine; may increase risk of seizures due to imipenem-cilastatin.
Onset: 38 d. Duration: Clinical relapse can occur 14 d to 3.5 mo after stopping therapy; positive blood and urine cultures recur 1260 d after
therapy. Distribution: Distributes throughout body including CSF, eye, lungs, liver, and kidneys; crosses placenta in animals; not known if distributed
into breast milk. Metabolism: Not metabolized. Elimination: 9499% of dose is excreted unchanged in urine. Half-Life: 2.54.2 h.
Assessment & Drug Effects
- Lab tests: Neutrophil and platelet counts at least every other day during twice-daily dosing and weekly thereafter; more frequent
monitoring may be indicated in certain patients. Monitor serum creatinine or creatinine clearance at least q2wk. Closely monitor
renal function in the older adult.
- Inspect IV insertion site throughout infusion for signs and symptoms of phlebitis.
Patient & Family Education
- Note: Drug is not a cure for CMV retinitis; follow regular ophthalmologic examination schedule.
- Drink lots of fluids during therapy.
- Use barrier contraception throughout therapy and for at least 90 d afterwards.
- Maintain frequent hematologic monitoring.
- Do not breast feed while taking this drug.